Posted by on Nov 29, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to investigate if first-line ibrutinib treatment was safe and effective in the long-term for patients with chronic lymphocytic leukemia.   This study concluded that single-agent ibrutinib provided good outcomes for patients when compared to the standard treatment chlorambucil in...

Read More